Effects of long-term ursodeoxycholate administration on expression levels of secretory low-molecular-weight phospholipases A2 and mucin genes in gallbladders and biliary composition in patients with multiple cholesterol stones.
Group IIA phospholipase A2 (PLA2), a secretory low-molecular-weight PLA2, may play a critical role in the process of gallbladder mucosal inflammation in multiple cholesterol stones, which in turn may produce biliary pronucleating proteins as well as mucin. On the other hand, ursodeoxycholate (UDC) decreases biliary levels of various pronucleating proteins, possibly because of its membrane-protective effects on the inflamed gallbladder mucosa. To elucidate that beneficial effect of UDC, the expression levels of low-molecular-weight PLA2s, group IIA PLA2 (PLA2-IIA), and group V PLA2 (PLA2-V), and mucin core polypeptide genes in the gallbladders were studied for UDC-treated patients and untreated patients with multiple cholesterol stones. Furthermore, the results were correlated with alterations in biliary composition. With long-term administration of UDC, the PLA2-IIA protein mass (2.7 +/- 0.5 vs. 5.0 +/- 0.4 ng/mg x protein [mean +/- SEM]; P < .01) and steady-state mRNA level, as well as the PLA2-V mRNA level, were significantly decreased in the gallbladders, where the prostaglandin E2 (PGE2) level was concomitantly decreased (190.7 +/- 27.9 vs. 393.6 +/- 55.3 pg/mg x protein; P < .01). In the gallbladder bile, the immunoradiometrically determined PLA2-IIA levels were significantly decreased in the UDC-treated patients (43 +/- 4 ng/dL; P < .01) in comparison with untreated patients (78 +/- 6 ng/dL). Significant decreases were similarly found for total protein, mucin, and free arachidonate concentrations, as well as nucleation activity in the bile. The degree of the changes was found to be rather small in solitary stones. In contrast to the decreased mucin concentration, however, there were no significant changes in the expression levels of mucin core polypeptide genes (MUC1-MUC6) between the UDC-treated and untreated patients. Long-term UDC administration was observed to lower the increased PLA2-IIA protein mass and mRNA level, as well as the PLA2-V mRNA level, in the gallbladders of patients with multiple cholesterol stones, which in turn may be of therapeutic importance in improving the gallbladder mucosal inflammation. Effects of UDC on secretory low-molecular-weight PLA2s as inflammatory mediators may relate to the reported efficacy of UDC treatment in cholesterol gallstone disease.
Kano
M
M
Department of Gastroenterology, Institute of Clinical Medicine, The University of Tsukuba, Ibaraki, Japan.
Shoda
J
J
Irimura
T
T
Ueda
T
T
Iwasaki
R
R
Urasaki
T
T
Kawauchi
Y
Y
Asano
T
T
Matsuzaki
Y
Y
Tanaka
N
N
D016718:Arachidonic Acid / Q000032:analysis; D001646:Bile / Q000737:chemistry; D002756:Cholagogues and Choleretics / Q000008:administration & dosage* / Q000627:therapeutic use; D002769:Cholelithiasis / Q000737:chemistry / Q000188:drug therapy* / Q000235:genetics*; D002784:Cholesterol / Q000032:analysis; D005704:Gallbladder / Q000502:physiology; D015870:Gene Expression / Q000187:drug effects*; D006801:Humans; D008055:Lipids / Q000032:analysis; D008970:Molecular Weight; D009077:Mucins / Q000235:genetics*; D010741:Phospholipases A / Q000737:chemistry / Q000235:genetics*; D054467:Phospholipases A2; D013997:Time Factors; D014580:Ursodeoxycholic Acid / Q000008:administration & dosage* / Q000627:therapeutic use
D002756:Cholagogues and Choleretics; D008055:Lipids; D009077:Mucins; D016718:Arachidonic Acid; D014580:Ursodeoxycholic Acid; D002784:Cholesterol; D010741:Phospholipases A; D054467:Phospholipases A2